[{"orgOrder":0,"company":"Accenture","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vestipitant","moa":"Neurokinin 1 receptor||Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Accenture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Accenture \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accenture \/ Undisclosed"},{"orgOrder":0,"company":"Accenture","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vestipitant","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Accenture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accenture \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accenture \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Vestipitant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Accenture

                          Country arrow
                          IPPE
                          Not Confirmed

                          Accenture

                          Country arrow
                          IPPE
                          Not Confirmed

                          Details : Vestipitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Postoperative Nausea and Vomiting.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 10, 2012

                          Lead Product(s) : Vestipitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Accenture

                          Country arrow
                          IPPE
                          Not Confirmed

                          Accenture

                          Country arrow
                          IPPE
                          Not Confirmed

                          Details : GW597599 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Postoperative Nausea and Vomiting.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 04, 2011

                          Lead Product(s) : Vestipitant

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank